Biotech company Hyperion Therapeutics raises $60m in Series C funding

6 Jul 2009

Hyperion Therapeutics, a San Francisco-based pharmaceutical company focusing on gastroenterology and hepatology, has closed a $60m round of Series C financing led by New Bay City Capital and Panorama Capital. They were joined by returning backers Highland Capital Partners, NEA, and Sofinnova Ventures.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.

NEWS & VIEWS

Global private equity and venture capital news and research

By News Type

By PE Sector

By Region

By Region

Country Focus

PE Focus

Industry Focus

Other

AltAssets Events

Industry Events